(Q35143993)

6 August 2017

1 reference

title

Farnesyl transferase inhibitors in clinical development (English)

1 reference

6 August 2017

Francesco Caponigro

1

1 reference

6 August 2017

Marina Casale

series ordinal

2

1 reference

6 August 2017

Jane Bryce

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

943-954

1 reference

6 August 2017

6

1 reference

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.943

10.1517/13543784.12.6.943

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference